Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products.
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... The Global and China Trifluoroacetic Acid Industry is ... of the Trifluoroacetic Acid industry in Global and China. ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... In a paper published this week in Science , ... and Professor Konstantin Novoselov has literally opened a third dimension ... prove the missing link for graphene to become the next ... is a remarkable material with endless unique properties, from ...
... 2012 InterMune, Inc. (NASDAQ: ITMN ) today ... year 2011 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 p.m. ... others may participate in the conference call by dialing 800-891-8257 ...
... Hudson, President and Scientific Director of The Ontario Institute ... to develop a framework for the implementation of personalized ... aims to integrate genomics research into everyday clinical practice, ... care for patients. Published in the journal ...
Cached Biology Technology:Graphene electronics moves into a third dimension 2InterMune to Release Fourth Quarter and Full Year Financial Results on February 9 2New Study Building Framework to Bring Personalized Medicine to the Clinic 2New Study Building Framework to Bring Personalized Medicine to the Clinic 3
(Date:8/28/2014)... available in German . ... built with the help of sophisticated assembly lines. Mobile assembly ... important part of these assembly lines. In the case of ... work stages arranged in a precise spatial and chronological sequence, ... line. , The creation of such an assembly line at ...
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Protected areas proven to protect biodiversity 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... Illinois at Chicago College of Pharmacy are attempting ... antipsychotic medication works in adults and children and ... a popular "atypical" antipsychotic medication, is used to ... disorder. , Jeffrey Bishop, assistant professor of ...
... With wheat stem sawfly natural enemies in demand, ... increasing their availability. , This fall, the ... mass-rearing parasitic wasps that attack wheat stem sawfly ... plants. The team includes entomologists David Weaver, master's ...
... tool developed at Cambridge University represents a breakthrough in ... Huntington's disease. , Researchers have developed an effective ... the disease, using an automated touch screen. It is ... more effectively the cognitive difficulties in other neurodegenerative disorders ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Rearing an army to save wheat 2Rearing an army to save wheat 3New technology to speed up research into Huntington's disease 2New technology to speed up research into Huntington's disease 3
ATGL Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Lipid Phosphate Phosphohydrolase 2...
Request Info...
Biology Products: